138 related articles for article (PubMed ID: 22907565)
1. Validation of a 30-year-old process for the manufacture of L-asparaginase from Erwinia chrysanthemi.
Gervais D; Allison N; Jennings A; Jones S; Marks T
Bioprocess Biosyst Eng; 2013 Apr; 36(4):453-60. PubMed ID: 22907565
[TBL] [Abstract][Full Text] [Related]
2. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
4. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
5. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli-asparaginase (Elspar) is superior to Erwinia-asparaginase (Erwinase) in childhood acute lymphoblastic leukaemia (ALL) induction--an early response study using minimal residual disease (MRD) markers.
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Ann Acad Med Singap; 2004 Sep; 33(5 Suppl):S45-6. PubMed ID: 15651203
[No Abstract] [Full Text] [Related]
8. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
9. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
10. Rapid large-scale preparation of recombinant Erwinia chrysanthemi L-asparaginase.
Goward CR; Stevens GB; Tattersall R; Atkinson T
Bioseparation; 1992; 2(6):335-41. PubMed ID: 1368993
[TBL] [Abstract][Full Text] [Related]
11. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
[TBL] [Abstract][Full Text] [Related]
12. [Update on L-asparaginase treatment in paediatrics].
Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
[TBL] [Abstract][Full Text] [Related]
13. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
15. l-Asparaginase and HCP quantification by SWATH LC-MS/MS for new and improved purification step in Erwinia chrysanthemil-asparaginase manufacture.
Modi T; Regufe da Mota S; Gervais D
J Pharm Biomed Anal; 2022 Feb; 209():114537. PubMed ID: 34929569
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
17. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
Ylikangas P; Mononen I
Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
[TBL] [Abstract][Full Text] [Related]
18. Determination of glycation levels in Erwinia chrysanthemi asparaginase drug product by liquid chromatography - mass spectrometry.
Kanda P; Minshull TC
Eur J Pharm Sci; 2020 Mar; 145():105253. PubMed ID: 32027934
[TBL] [Abstract][Full Text] [Related]
19. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
20. Asparaginases: where do we go from here?
Ettinger LJ
J Pediatr Hematol Oncol; 1999; 21(1):3-5. PubMed ID: 10029804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
